Latest Commercialization News

Nickel Industries reveals a substantial Exploration Target of 350 to 700 million dry metric tonnes at 0.9% to 1.1% nickel for its Sampala Project, complementing an existing 187 million dmt resource. The company has initiated mine development and haul road construction, positioning itself for a secure nickel supply chain.

Australian Strategic Materials (ASM) has secured a $5 million federal grant to accelerate its Dubbo Project, progressing rare earth recovery innovations while navigating a complex global market landscape.

Buxton Resources reports robust drilling results at its Graphite Bull and Narryer projects, completes Stage 1 earn-in on Copper Wolf JV with IGO, and undertakes key board changes, positioning itself for an active 2025 exploration season.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Intelligent Monitoring Group Limited has reaffirmed its FY25 adjusted EBITDA guidance above $38 million, reporting a robust $7.9 million operating cash flow for the first half of 2025. The company is advancing its strategic acquisitions and launching innovative video guarding services poised to disrupt the security sector.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.